Back to search results

Observational Study of Semaglutide for Overweight and Obesity

This observational study is looking at how people with overweight or obesity respond to treatment with semaglutide, a GLP-1 receptor agonist. Researchers want to understand why some people have a better blood pressure and weight loss response to this medication than others. You might be eligible if you are at least 18 years old, have a BMI of 30 or higher (or 27 with certain health conditions like high blood pressure), and have normal lab values. The study will measure your blood pressure and weight response after 20 weeks of semaglutide therapy. The study aims to enroll 30 participants.

Study design
This is an observational study with 30 participants. It is not specified if it is randomized or blinded.
What's involved
You will have 24-hour ambulatory blood pressure, blood, and urine tests before starting semaglutide and again after 20 weeks of treatment. You will also follow a liberal salt diet for 7 days.
Compensation
Not stated in the trial record.
Follow-up
Your blood pressure and weight loss response will be measured after 20 weeks of semaglutide therapy.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06069622

Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment

Recruiting
Not specifiedAges 18+Observational
Brigham and Women's Hospital
~30 participants
Updated 2025-12-10 on ClinicalTrials.gov
What's tested:24-hour ambulatory blood pressureLiberal salt diet

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Blood pressure response to GLP-1 RA treatment
Measured over 20 weeks
+1 more outcome measured

Conditions

Overweight and Obesity

Explore related trials

Obesity

Where it's being run

1 sites across 1 states
Massachusetts1

Who to contact

Ezgi Caliskan Guzelce, M.D.
[email protected]
857-544-4290
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥18 years, body mass index (BMI) ≥30.0 kg/m2 or ≥27.0 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, prediabetes, dyslipidemia, obstructive sleep apnea,
Normal screening laboratory values,
Systolic BP \< 160 mmHg and diastolic BP \< 95 mmHg as determined from measurement during screening, using a random-zero device in the clinic and normal electrocardiogram, use of anti-hypertensive medications will be allowed except for mineralocorticoid receptor antagonists.

Exclusion

Diabetes mellitus,
Treatment with a glucose-lowering agent(s) or anti-obesity medication within 90 days of screening,
Treatment with a GLP-1 receptor agonist within 180 days,
Current treatment with beta-blocker, or steroids,
Pregnancy,
Personal history of pancreatitis,
Personal history of cholelithiasis,
Previous surgical obesity treatment,
Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma,
Medical illness other than hypertension, prediabetes, obstructive sleep apnea, or dyslipidemia,
Alcohol intake \>12 oz. per week,
Tobacco, or recreational drug use

What this trial measures

  • Blood pressure response to GLP-1 RA treatment20 weeks

    The primary outcome will be the change (pre- treatment minus post-treatment) in mean 24-hour ambulatory systolic BP on a controlled dietary sodium intake in both CAV1 non-risk and risk genotypes.

  • Weight loss response to GLP-1 RA treatment20 weeks

    The primary outcome will be the mean percent change (pre- treatment minus post-treatment) in body weight in both CAV1 non-risk and risk genotypes.